TD Cowen Maintains Buy on Elevance Health, Lowers Price Target to $589
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ryan Langston maintains a Buy rating on Elevance Health (NYSE:ELV) but lowers the price target from $624 to $589.

July 19, 2024 | 4:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TD Cowen analyst Ryan Langston maintains a Buy rating on Elevance Health (NYSE:ELV) but lowers the price target from $624 to $589.
The maintained Buy rating suggests continued confidence in Elevance Health's performance, but the lowered price target indicates some caution about its short-term prospects. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100